Scilex Holding Company

SCLXNASDAQ · Biological Products, (No Diagnostic Substances)

Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

7.03M

on 2026-06-30, from 3.03M on 2024-03-31 10-Q ↗

Earlier counts are adjusted for the 1-for-35 reverse split; each bar's tip shows the count as filed.

Newest

$500.0M

S-3 of 2026-04-16. None sold under it to 2026-10-05. S-3 ↗

$170.0M

B. Riley Securities, agreement of 2024-01-11. No at-the-market sales statement read from a 10-Q or 10-K. 424B3 ↗

Warrants

5.47M

Warrants of every class as tagged in the XBRL facts on 2026-06-30. 10-Q ↗

Cash

0.1 quarters

$566K on 2026-06-30 ÷ $4.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 61 of its filings are not read yet.

Also on file: a 1-for-35 reverse split, 2025-04-14 8-K ↗ · up to $50.0M notes agreed 2025-12-01 8-K ↗ · up to $50.0M notes agreed 2025-12-08 8-K ↗ · up to $100.0M notes agreed 2025-12-16 8-K ↗ · up to $20.0M promissory note agreed 2026-08-08 8-K ↗ · up to $20.0M promissory note agreed 2026-09-25 8-K ↗